



























	 Arylhydrazines	reacted	with	dehydroacetic	acid	(1)	to	give	the	corresponding	2H‐pyran‐2‐onehydrazones	 (2),	 which	 on	 treatment	 with	 hydrazine	 hydrate	 afforded	 the	 corresponding
1‐amino‐2H‐pyridin‐2‐ones	 (3).	 Reaction	 of	 3	 with	 nitrous	 acid,	 aromatic	 aldehyde	 and
substituted	 benzenesulfonyl	 chlorides	 yielded	 the	 corresponding	 2H‐pyridine‐2‐one











In	 recent	 years,	 the	 number	 of	 life	 threatening	 infections	
caused	 by	 multi‐drug	 resistant	 Gram	 positive	 and	 Gram	
negative	pathogenic	bacteria	has	 reached	an	alarming	 level	 in	
many	 countries	 around	 the	world;	 consequently	 the	 need	 for	
the	 synthesis	 of	 novel	 antibiotics	 is	 a	 reality.	 However,	
investigations	 in	 the	 chemistry	and	biology	of	2‐pyrones	have	
become	 that	 they	 constitute	 an	 essential	 pharmacophore	 in	
many	 naturally	 occurring	 and	 biologically	 active	 agents	 [1].	
Literature	 survey	 revealed	 that	 a	 simple	 change	 in	 the	
substitution	pattern	on	the	2‐pyrone	ring	often	leads	to	diverse	
biological	activities.	
For	 example,	 some	 2‐pyrone	 derivatives	 are	 yeast	 lipase	
(CRLI),	 cholesterol	 esterase	 (CRL3)	 inhibitors	 [3],	 anti‐
inflammatory	 [4,5]	 and	 immune	 suppressive	 [6]	 agents.	
Particular	 attention	 has	 been	 focused	 on	 the	 distinctive	
chemotherapeutic	 activity	 of	 2‐pyrones	 as	 cytotoxic	 agents	
against	some	human	cancer	cell	lines	[7,8],	anti‐HIV	[9,10]	and	
potential	 antimicrobial	 agents	 [11,12].	 On	 the	 other	 hand,	 a	
broad	 spectrum	 of	 pharmacological	 properties	 has	 been	
ascribed	to	the	structurally‐relevant	2‐pyridone	derivatives.	In	
addition	 to	 their	 pronounced	 effects	 on	 the	 cardiovascular	
system	 as	 cardiotonic	 [13,14],	 calcium	 channel	 blocking	 [15]	
and	 tissue	 factor	 VII	 inhibitory	 agents	 [16],	 some	 pyridones	
were	 reported	 to	 exhibit	 potential	 antimicrobial	 [17‐20],	
antitubercular	 [21,22],	 antiamoebic	 [23],	 antiparasitic	 [24],	
antimalarial	[25],	antifungal	and	antiviral	[26‐28]	activities.	
N‐Substituted	pyrazolyl‐benzensulfonamides	are	known	to	
show	 COX‐2	 selective	 inhibition	 [29],	 thioureide	 analogs	 of						
2‐phenetilbenzoic	 acid	 and	 pyridazine	 derivatives	 carrying	






synthesize	 the	 hybrid	 molecule	 through	 a	 combination	 of	
pyridone	and	hydrazide	pharmacophores	in	one	structure	with	
the	 hope	 of	 obtaining	 better	 antibacterial	 and/or	 antifungal	
agents.	 Therefore,	 we	 have	 synthesized	 a	 series	 of	 new	 2‐
pyrone	 and	 their	 2‐pyridone	 analogs	 (Scheme	 1	 and	 2),	








a	 Gallenkamp	melting	 point	 apparatus	 and	were	 uncorrected.	
The	 infrared	(IR)	spectra	were	recorded	on	Perkin‐Elmer	297	
infrared	 spectrophotometer	using	 the	plate	 technique.	The	 1H	
NMR	and	13C	NMR	spectra	were	recorded	on	Bruker	DPX‐400‐
FT	 spectrometer	 using	 CDCl3	 and	 DMSO‐d6	 as	 a	 solvent	 and	
tetramethylsilane	as	the	 internal	standard.	Elemental	analyses	
were	performed	at	the	Microanalytical	Unit,	Faculty	of	Science,	
Cairo	University,	 Cairo,	 Egypt.	 Follow	 up	 of	 the	 reactions	 and	
checking	 the	 homogeneity	 of	 the	 compounds	 were	 made	 by	
Thin	 layer	 chromatography	 (TLC)	 on	 silica	 gel‐protected	
aluminum	 sheets	 (Type	 60	 F254,	 Merck)	 and	 the	 spots	 were	
detected	 by	 exposure	 to	 UV	 lamp	 at	 λ	 =	 254	 nm.	 Biological	












Aldrich	 Chemical	 Co.,	 Milwaukee,	 USA	 and	 was	 used	 without	
further	 purification.	 The	 characterization	 data	 of	 the	







the	 appropriate	 aryl	 hydrazine	 (10	 mmol).	 The	 mixture	 was	
refluxed	for	15	min	and	allowed	to	stand	at	room	temperature	






A	 solution	 of	 the	 appropriate	 hydrazone	 2	 (10	 mmol)	 in	
ethanol	(20	mL)	was	refluxed	with	hydrazine	hydrate	98%	(1.1	
mL,	22	mmol)	 for	2	h.	The	reaction	mixture	was	concentrated	
to	 half	 its	 volume	 and	 allowed	 to	 cool.	 The	 solid	 product	














C H N S C	 H	 N S
2a	 C6H5	 	 82	 212a C14H14N2O3 65.11 5.46 10.85 56.21	 5.54	 10.94
2b	 p‐H2NSO2C₆H₄	 	 85	 255	 C14H15N3O5S 49.84 4.48 12.46 9.51	 49.72	 4.51	 12.47 9.62
2c	 p‐ClC₆H₄	 	 78	 218	 C14H13ClN2O3 57.44 4.48 9.57 57.45	 4.53	 9.62
2d	 p‐FC₆H₄	 	 74	 212	 C14H13FN2O3 60.87 4.74 14.01 60.81	 4.76	 13.98
2e	 p‐NO2C₆H₄	 	 78	 216	 C14H13N3O5 55.45 4.32 13.86 55.48	 4.42	 13.93
3a	 C6H5	 	 69	 233	 C14H16N4O2 61.75 5.92 20.58 61.84	 6.02	 20.67
3b	 p‐H2NSO2C₆H₄	 	 70	 192	 C14H17N5O4S 47.85 4.88 19.93 9.13	 47.92	 4.92	 20.11 9.23
3c	 p‐ClC₆H₄	 	 63	 250	 C14H15ClN4O2 54.82 4.93 18.26 54.97	 5.04	 18.18
3d	 p‐FC₆H₄	 	 60	 216	 C14H15FN4O2 57.92 5.21 19.31 57.84	 5.12	 19.42
4a	 C6H5	 	 	 204	 C14H15N3O2 65.35 5.88 16.33 65.45	 5.97	 16.45
4b	 p‐ClC₆H₄	 	 	 231	 C14H14ClN3O2 57.64 4.84 14.41 57.81	 4.93	 14.38
4c	 p‐FC₆H₄	 	 	 223	 C14H14FN3O2 61.08 5.13 15.26 61.12	 5.16	 15.37
5a	 C6H5	 Cyclohexyl 68	 169	 C21H27N5O3 63.46 6.85 17.62 63.58	 6.92	 17.74
5b	 C6H5	 C6H5	 70	 205	 C21H21N5O3 64.44 5.41 17.89 64.54	 5.38	 17.92
5c	 C6H5	 p‐ClC₆H₄	 68	 214	 C21H20ClN5O3 59.23 4.73 16.44 59.34	 4.82	 16.54
5d	 p‐ClC₆H₄	 Cyclohexyl 72	 264	 C21H26ClN5O3 58.41 6.07 16.21 58.33	 6.18	 16.38
5e	 p‐ClC₆H₄	 C6H5	 74	 249	 C21H20ClN5O3 59.23 4.73 16.44 59.28	 4.84	 16.36
5f	 p‐ClC₆H₄	 p‐ClC₆H₄	 70	 259	 C21H19Cl2N5O3 54.79 4.16 15.21 54.82	 4.27	 15.22
5g	 p‐FC₆H₄	 C6H5	 66	 218	 C21H20FN5O3 61.61 4.92 17.11 61.73	 5.11	 17.31
5h	 p‐FC₆H₄	 p‐ClC₆H₄	 68	 248	 C21H19ClFN5O3 56.83 4.31 15.78 56.71	 4.23	 15.87
6a	 C6H5	 CH3	 69	 260	 C16H19N5O2S 55.63 5.54 20.27 9.28	 55.54	 5.48	 20.32 9.31
6b	 C6H5	 CH3(CH3)2CH2	 66	 249	 C19H25N5O2S 58.89 6.51 18.07 8.27	 58.97	 6.58	 17.18 8.38
6c	 C6H5	 C6H5	 72	 254	 C21H21N5O2S 61.91 5.19 17.19 7.87	 61.87	 5.23	 16.76 7.94
6d	 C6H5	 p‐CH3C₆H₄ 70	 262	 C22H23N5O2S 62.69 5.51 16.61 7.61	 62.79	 5.62	 16.58 7.62
6e	 C6H5	 p‐FC₆H₄	 69	 216	 C21H20FN5O2S 59.28 4.74 16.46 7.54	 59.41	 4.78	 16.48 7.53
6f	 p‐ClC₆H₄	 C6H5	 72	 266	 C21H20ClN5O2S 57.07 4.56 15.85 7.26	 57.14	 4.66	 15.92 7.34
6g	 p‐ClC₆H₄	 p‐CH3C₆H₄ 74	 241	 C22H22ClN5O2S 57.95 4.86 15.36 7.03	 58.12	 4.89	 15.44 7.11
6h	 p‐ClC₆H₄	 p‐FC₆H₄	 68	 257	 C21H19ClFN5O2S 54.84 4.16 15.23 6.97	 54.86	 4.23	 15.41 7.04
6i	 p‐FC₆H₄	 C6H5	 67	 252	 C21H20FN5O2S 59.28 4.74 16.46 7.54	 59.37	 4.86	 16.55 7.63
7a	 C6H5	 C6H5	 72	 238	 C21H20N4O2 69.98 5.59 15.55 70.11	 5.62	 15.64
7b	 C6H5	 p‐CH3C₆H₄ 74	 226	 C22H22N4O2 70.57 5.92 14.96 70.48	 6.02	 15.04
7c	 C6H5	 p‐CH3OC₆H₄ 68	 230	 C22H22N4O3 67.68 5.68 14.35 67.79	 5.74	 14.42
7d	 C6H5	 p‐ClC₆H₄	 72	 242	 C21H19ClN4O2 63.88 4.85 14.19 63.92	 4.94	 14.25
7e	 C6H5	 2‐Thienyl	 76	 235	 C19H18N4O2S 62.28 4.95 15.29 62.31	 5.11	 15.41
7f	 p‐ClC₆H₄	 C6H5	 78	 199	 C21H19ClN4O2 63.88 4.85 14.19 63.77	 4.76	 14.28
7g	 p‐ClC₆H₄	 p‐ClC₆H₄	 76	 216	 C21H18Cl2N4O2 58.75 4.23 13.05 58.84	 4.24	 13.16
7h	 p‐ClC₆H₄	 2‐Thienyl	 72	 222	 C19H17ClN4O2S 56.93 4.27 13.98 57.12	 4.39	 14.01
7i	 p‐FC₆H₄	 C6H5	 69	 220	 C21H19FN4O2 66.66 5.06 14.81 66.75	 5.08	 14.92
7j	 p‐FC₆H₄	 p‐ClC₆H₄	 66	 218	 C21H18ClFN4O2 61.09 4.39 13.57 61.12	 4.42	 13.64
7k	 p‐FC₆H₄	 2‐Thienyl	 68	 209	 C19H17FN4O2S 59.36 4.46 14.57 59.43	 4.61	 15.46
8a	 C6H5	 C6H5	 76	 178	 C20H20N4O4S 58.24 4.89 13.58 7.77	 58.13	 4.91	 13.62 7.86
8b	 C6H5	 p‐CH3C₆H₄ 78	 162	 C21H22N4O4S 59.14 5.21 13.14 7.52	 59.24	 5.32	 13.24 7.45
8c	 p‐ClC₆H₄	 C6H5	 77	 136	 C20H19ClN4O4S 53.75 4.29 12.54 7.17	 53.88	 4.41	 12.63 7.21
8d	 p‐FC₆H₄	 C6H5	 76	 138	 C20H19FN4O4S 55.81 4.45 13.02 7.45	 55.92	 4.61	 13.12 7.56
8e	 p‐FC₆H₄	 p‐CH3C₆H₄ 78	 164	 C21H21FN4O4S 56.75 4.76 12.61 7.21	 56.82	 4.79	 12.75 7.34
9a	 	 Cyclohexyl 74	 172	 C21H26N4O6S 54.53 5.67 12.11 6.93	 54.64	 5.73	 12.21 7.11
9b	 	 C6H5	 72	 192	 C21H20N4O6S 55.26 4.42 12.27 7.02	 55.37	 4.43	 12.36 7.15
9c	 	 p‐ClC₆H₄	 78	 163	 C21H19ClN4O6S 51.38 3.91 11.41 6.53	 51.49	 4.02	 11.56 6.48
10a	 	 CH3	 70	 189	 C16H18N4O5S2 46.82 4.42 13.65 15.62	 46.88	 4.34	 13.78 15.74
10b	 	 Cyclohexyl 72	 199	 C21H26N4O5S2 52.71 5.48 11.71 13.41	 52.82	 5.52	 11.82 13.48
10c	 	 CH2C6H5	 70	 168	 C22H22N4O5S2 54.31 4.56 11.51 13.18	 54.42	 4.64	 15.68 13.02
10d	 	 C6H5	 70	 152	 C21H20N4O5S2 53.38 4.27 11.86 13.57	 53.51	 4.38	 11.99 13.43
10e	 	 p‐CH3C₆H₄ 77	 148	 C22H22N4O5S2 54.31 4.56 11.51 13.18	 54.44	 4.62	 11.54 13.08
10f	 	 p‐FC₆H₄	 72	 151	 C21H19FN4O5S2 51.42 3.91 11.42 13.07	 51.56	 4.14	 11.58 13.15
11a	 	 Cyclohexyl 72	 215	 C28H39N7O6S 55.89 6.53 16.29 5.33	 55.92	 6.58	 16.41 5.38
11b	 	 C6H5	 70	 243	 C28H27N7O6S 57.04 4.62 16.63 5.44	 57.13	 4.73	 16.74 5.42
11c	 	 p‐ClC₆H₄	 72	 236	 C28H25Cl2N7O6S 51.07 3.83 14.89 4.87	 51.12	 3.94	 14.78 5.96
12a	 	 Cyclohexyl 73	 229	 C28H39N7O4S3 53.06 6.21 15.47 15.18	 53.18	 6.12	 15.52 15.09
12b	 	 CH3	 70	 237	 C18H23N7O4S3 43.45 4.66 19.71 19.33	 43.61	 4.75	 19.83 19.32
12c	 	 CH3(CH2)2CH2	 68	 244	 C24H35N7O4S3 49.55 6.06 16.85 16.53	 49.64	 6.17	 16.92 16.64
12d	 	 C6H5	 70	 242	 C28H27N7O4S3 54.09 4.38 15.77 15.47	 54.12	 4.42	 15.91 15.52
12e	 	 p‐CH3C₆H₄ 69	 250	 C30H31N7O4S3 55.45 4.81 15.09 14.81	 55.54	 4.96	 15.13 14.71







A	 solution	 of	 the	 appropriate	 1‐amino‐2‐pyridone	
derivative	3	(2	mmol)	in	glacial	acetic	acid	(10	mL)	was	treated	
(drop	wise)	with	an	aqueous	solution	of	sodium	nitrite	(0.5	g)	








To	 the	 solution	 to	 the	 appropriate	 aminopyridone	 3	 (2	
mmol)	 in	 pyridine	 (10	 mL)	 was	 added	 the	 appropriate	
isocyanate	 (2.1	 mmol),	 and	 the	 reaction	 mixture	 was	 heated	
under	 reflux	 for	 8	 h.	 After	 cooling	 to	 room	 temperature,	 the	
reaction	mixture	was	poured	on	crushed	ice	and	the	separated	






Comp.	 R	 R1	or	R2 CH3	 H‐5 Ar‐H NH OH Others	
(s,	3H)	 (s,	1H) (m) (s,	1H) (s,	1H)
2a	 C6H5	 	 1.03,	1.52	 5.99 6.62‐7.01 7.85 14.28 	
2b	 p‐NH2SO2C₆H₄	 	 1.17,	1.62	 6.22 6.85‐7.72 8.02 14.46 	
2c	 p‐ClC₆H₄	 	 0.95,	1.41	 6.36 6.45‐6.98 7.62 14.82 	
2d	 p‐FC₆H₄	 	 1.05,	1.38	 6.24 6.48‐6.76 7.71 14.26 	
2e	 p‐NO2C₆H₄	 	 1.08,	1.47	 6.21 6.25‐7.01 8.96 15.02 	
3a	 C6H5	 	 1.13,	1.43	 5.02 6.62‐7.12 7.58 14.52 	
3b	 p‐NH2SO2C₆H₄	 	 1.12,	1.41	 5.34 6.47‐7.68 7.94 13.84 	
4a	 C6H5	 	 1.03,	1.54	 5.52 6.62‐7.68 7.72,	8.12 14.92 	
4b	 p‐ClC₆H₄	 	 1.12,	1.42	 5.34 6.71‐7.03 7.64,	8.06 15.03 	
4c	 p‐FC₆H₄	 	 0.98,	1.38	 5.28 6.74‐7.26 7.52,	8.03 14.74 	
5a	 C6H5	 Cyclohexyl 1.10,	1.55	 5.46 6.81‐7.71 6.62,	6.75,	8.57 13.98 1.32‐2.63	(m,	11H,	cyclohexyl)
5b	 C6H5	 C6H5	 1.04,	1.52	 5.29 6.93‐7.68 6.74,	6.84,	8.61 14.05 	
5e	 p‐ClC₆H₄	 C6H5	 1.18,	1.49	 5.34 7.01‐7.79 6.88,	6.94,	8.43 13.24 	
5f	 p‐ClC₆H₄	 p‐ClC₆H₄ 1.05,	1.54	 5.22 6.74‐7.84 7.26,	8.64,	8.94 14.46 	
5g	 p‐FC₆H₄	 C6H5	 0.98,	1.37	 5.34 6.62‐7.68 7.85,	8.32,	8.75 14.04 	
6a	 C6H5	 CH3	 0.95,	1.41	 5.29 6.63‐7.02 7.24,	7.56,	8.66 15.13 3.45	(d,	3H,	NCH3)	
6c	 C6H5	 C6H5	 1.01,	1.46	 5.38 6.72‐7.41 7.64,	7.83,	9.12 14.28 	
6d	 C6H5	 p‐CH3C₆H₄ 1.24,	1.53	 5.42 6.83‐7.78 7.83,	8.72 12.98 3.13	(s,	3H,	CH3)	
6g	 p‐ClC₆H₄	 p‐CH3C₆H₄ 1.18,	1.49	 5.39 6.64‐7.76 7.94,	8.82 13.56 3.08	(s,	3H,	CH3)	
6i	 p‐FC₆H₄	 C6H5	 1.07,	1.33	 5.26 6.56‐7.64 7.74,	7.92,	8.45 14.03 	
7a	 C6H5	 C6H5	 1.12.	1.46	 5.28 6.78‐7.75 7.95 12.98 8.21	(s,	1H,	CH=)	
7b	 C6H5	 p‐CH3C₆H₄ 1.23,	1.50	 5.36 6.67‐7.58 8.38 13.56 3.14	(s,	3H,	CH3),	8.16	(s,	1H,	CH=)
7c	 C6H5	 p‐CH3OC₆H₄	 1.25,	1.46	 5.42 6.89‐7.79 8.61 13.42 3.85	(s,	3H,	CH3O),	8.12	(s,	1H,	CH=)
7f	 p‐ClC₆H₄	 C6H5	 1.18,	1.38	 5.39 6.77‐7.68 8.56 14.05 8.24	(s,	1H,	CH=)	
8a	 C6H5	 C6H5	 1.20,	1.36	 5.25 6.80‐7.72 8.05,	8.42 14.36 	
8e	 p‐FC₆H₄	 p‐CH3C₆H₄ 1.22,	1.48	 5.34 6.74‐7.81 8.16,	8.89 13.88 3.12	(s,	3H,	CH3)	
9a	 	 Cyclohexyl 0.98,	1.50	 6.22 6.68‐7.42 7.82,	8.05,	8.56 12.98 1.35‐2.84	(m,	11H,	cyclohexyl)
9b	 	 C6H5	 1.15,	1.54	 6.34 6.72‐7.64 8.12,	8.34,	8.74 14.45 	
10a	 	 CH3	 1.12,	1.49	 6.28 6.84‐7.36 8.06,	8.42,	8.68 13.92 3.38	(d,	3H,	CH3)	
10c	 	 CH2C6H5 1.20,	1.56	 6.42 6.94‐7.65 7.98,	8.14,	8.78 12.78 4.57	(d,	2H,	CH2)	
10d	 	 C6H5	 1.17,	1.65	 6.27 6.68‐7.62 7.86,	8.03,	8.66 14.15 	
11a	 	 Cyclohexyl 1.14,	1.68	 5.28 6.72‐7.34 7.94,	8.05,	8.56,	8.84 14.25 1.22‐3.05	(m,	22H,	2cyclohexyl)
11b	 	 C6H5	 1.22,	1.56	 5.32 6.64‐7.58 7.82,	8.14,	8.35,	8.82 13.98 	
12a	 	 Cyclohexyl 1.02,	1.59	 5.41 6.76‐7.49 8.01,	8.25,	8.67,	9.11 13.67 1.18‐3.14	(m,	22H,	2cyclohexyl)
12d	 	 C6H5	 1.06,	1.63	 5.29 6.65‐7.78 8.14,	8.42,	8.90,	9.24 14.18 	








To	 a	 solution	of	 the	 appropriate	3	 derivative	 (2	mmol)	 in	








appropriate	 aldehyde	 (1	 mmol)	 in	 benzene	 (10	 mL)	 was	
refluxed	 for	 5	 h.	 Excess	 solvent	 was	 removed	 under	 reduced	







To	 a	 solution	of	 the	 appropriate	3	 derivative	 (1	mmol)	 in	
pyridine	 (10	mL)	was	 added	 the	 appropriate	 benzenesulfonyl	
chloride	 derivative	 (1.1	 mmol),	 and	 the	 mixture	 was	 heated	
under	 reflux	 for	 4	 h.	 After	 cooling	 to	 room	 temperature,	 the	
reaction	mixture	was	poured	on	crushed	ice	and	the	separated	








To	 a	 solution	 of	2b	 (0.34	 g,	 1	mmol)	 in	 pyridine	 (10	mL)	
was	 added	 the	 appropriate	 isocyanate	 or	 isothiocyanate	 (1.1	
mmol),	and	the	reaction	mixture	was	heated	under	reflux	for	5‐








To	 a	 solution	 of	3b	 (0.35g,	 2	 mmol)	 in	 pyridine	 (10	mL)	











Standard	 sterilized	 filter	 paper	 discs	 (5	 mm	 diameter)	
impregnated	with	a	solution	of	the	test	compound	in	dimethyl	
sulfoxide	 (DMSO)	 (1	 mg/mL)	 was	 placed	 on	 an	 agar	 plate	
seeded	 with	 the	 appropriate	 test	 organism	 in	 triplicates.	 The	
utilized	 test	 organisms	 were:	 Staphylococcus	 aureus	 (ATCC	
25923)	and	Bacillus	subtilis	(	ATCC	6051)	as	examples	of	Gram	
positive	 bacteria,	 Escherichia	 coli	 (ATCC	 25922)	 and	
Pseudomonas	 aeruginosa	 (ATCC	 27853)	 as	 examples	 of	 Gram	
negative	 bacteria,	 Candida	 albicans	 (ATCC	 10231)	 and	
Aspergillus	 niger	 (recultured)	 as	 representatives	 of	 fungi.	








Comp.	 R	 R1	or	R2	 CH3	 Pyrone	or
Pyridone	C	
ArC C=N Others	





	 	 	 161.0,	175.2 	





	 	 	 160.7,	174.1 	





	 	 	 160.9,	172.3 	





	 	 	 160.2,	171.2 	





	 	 	 162.8,	173.4 	





	 	 	 163.3,	169.9 	





	 	 	 161.7,	170.4 163.2	(cyclohexyl)	(CO)







	 	 	 160.4,	168.6 	





	 	 22.3	 161.3,	171.8 128.1,	130.7,	139.2,	
140.1	
	





	 	 	 163.6,	168.4 131.8,	136.7,	137.9,	
141.2	
	





	 	 23.2	 160.5,	171.6 128.2,	130.6,	138.7,	
143.5	
	





	 	 	 161.9,	170.4 129.3,	132.6,	138.8,	
142.1	
163.8	(cyclohexyl)	(CO)	 	





	 	 	 160.8,	173.4 	





	 	 33.2	 161.9,	172.9 	
a	Solution	in	a	mixture	of	CDCl3	and	DMSO‐d6.	
	








MICs	 were	 measured	 for	 compounds	 that	 showed	
significant	 growth	 inhibition	 zones	 (≥	12	mm)	using	 the	 two‐
fold	 serial	 dilution	 technique	 [35].	 The	 microdilution	
susceptibility	 test	 in	 Muller‐Hinton	 Broth	 (Oxoid)	 and	
Sabouraud	 Liquid	 Medium	 (Oxoid)	 was	 used	 for	 the	
determination	 of	 antibacterial	 and	 antifungal	 activity,	




µg/mL).	 The	 microorganism	 suspensions	 at	 106	 CFU/mL	








The	 available	 Mycobacterium	 tuberculosis	 strain	 was	
cultured	 in	 tubes	with	 10	 µL	 of	 a	 suspension	 of	 the	 strain	 in	
physiological	 saline.	 The	 strain	 was	 collected	 from	 the	 slant	
after	 four	weeks	 incubation	 [36].	The	 inoculum	was	prepared	
with	3‐5	weeks	old	M.	tuberculosis	colonies	from	Loewenstein‐
Jensen	 slants,	 emulsified	 in	 dilution	 fluid	 containing	 2%	 fatty	
acid	free	albumin	and	0.02%	Tween	80,	pH	=	6.9.	Suspensions	
were	 then	 diluted	 in	 saline	 to	 a	 turbidity	 of	 McFarland	 no.1	
standard	and	 then	diluted	 to	obtain	 inocula	of	3x105	cells	per	
well.	 The	 MICs	 measurements	 were	 determined	 by	 agar	
dilution	 technique.	Agar	 supplemented	with	10%	OADC	 (oleic	
acid‐albumin‐dextrose‐catalase)	 enrichment,	 was	 used	 to	
prepare	quadrant	plates	with	serial	DMSO	two‐fold	dilutions	of	
the	 test	 compounds.	 The	 following	 concentrations	were	 used:	
1000,	500,	250,	125,	62,	32,	16,	8,	4	µg/mL.	A	100	µL	sample	of	
the	 mycobacterial	 suspension	 was	 inoculated	 onto	 each	
compound‐containing	quadrant.	Control	quadrant	consisted	of	
agar	 alone,	 culture	 medium	 with	 DMSO	 and	 culture	 medium	
with	 reference	 antimycobacterial	 drugs;	 rifampicin	 and	 1HN	
was	performed.	All	plates	were	then	incubated	at	37	oC	in	a	CO2	
(5%	CO2	/	95%	humidified	air)	 incubator,	 for	3‐4	weeks.	The	
















IZa	 MICb	 IZa	 MICb	 IZa	 MICb	 IZa	 MICb	 IZa	 MICb	
2a	 12	 >200	 10	 ...c	 7 ... NAd ... 7	 ...
2b	 20	 100	 17	 100 14 200 10 ... 14	 100
2c	 14	 100	 12	 200 8 ... NA ... 9	 ...
3a	 18	 100	 15	 200 9 ... NA ... 9	 ...
3b	 22	 100	 17	 100 14 200 10 ... 16	 100
3c	 24	 50	 20	 50	 15 200 11 ... 23	 50
4a	 19	 50	 18	 100 6 ... NA ... 8	 ...
5a	 28	 12.5	 22	 50	 17 50 14 200	 29	 25
5b	 12	 >200	 11	 ….	 8 ... 6 ... 18	 50
5c	 23	 50	 18	 100 16 200 11 ... 18	 50
5d	 20	 100	 17	 100 12 200 10 ... 14	 100
6a	 3	 ...	 4	 ...	 NA ... NA ... NA	 ...
6b	 5	 ...	 6	 ...	 NA ... NA ... NA	 ...
7a	 12	 >200	 10	 ...	 8 ... NA ... 10	 ...
7b	 6	 ...	 7	 ...	 NA ... NA ... NA	 ...
7c	 4	 ...	 3	 ...	 6 ... NA ... 9	 ...
8a	 18	 100	 16	 200 10 ... NA ... 8	 ...
8b	 20	 50	 18	 50	 14 200 10 ... 16	 100
9a	 13	 >200	 10	 ...	 8 ... 6 ... 14	 100
9b	 18	 100	 12	 200 10 ... NA ... 9	 ...
9c	 12	 >200	 9	 ...	 8 ... NA ... 6	 ...
10a	 3	 ...	 4	 ...	 NA ... NA ... NA	 ...
10b	 5	 ...	 6	 ...	 NA ... NA ... NA	 ...
11a	 14	 100	 15	 200 12 200 10 ... 22	 50
11b	 16	 100	 17	 50	 14 100 13 ... 18	 100
11c	 24	 50	 20	 50	 10 100 12 ... 16	 100
12a	 3	 ….	 4	 …	 NA ... NA ... 2	 ...
A*	 36	 12.5	 30	 25	 32 25 27 50	 ...	 ...








Dehydroacetic	 acid	 has	 been	 reported	 to	 generate	 a	
number	 of	 heterocyclic	 compounds	 through	 ring	 opening	 and	
recyclization	 upon	 treatment	 with	 a	 variety	 of	 binucleophiles	
[37‐41].	 In	 1991	 Bendaas	 et	 al.	 reported	 the	 synthesis	 of	 4‐
acylacetyl‐5‐hydroxy‐1‐phenylpyrazoles	(I)	[42]	(Scheme	3).	In	












the	 hydrazinolysis	 reaction	 of	 1	 afforded	 the	 corresponding	
hydrazones	(2a‐e).	
The	 IR	 spectra	 of	 these	 hydrazones	 revealed	 carbonyl	
absorption	 at	 1720‐1738	 cm‐1	 as	well	 as	 an	OH	absorption	 in	
the	region	3520‐3600	cm‐1.	Their	1H	NMR	spectra	in	agreement	
with	 the	 suggested	 structures	 which	 showed	 besides	 the	
methyl	 and	 aromatic	 protons	 two	 singlets	 at	 	 5.99‐6.36	 and	
14.26‐15.02	 for	 H‐5	 and	 OH,	 respectively	 (Table	 2).	 The	
structures	 were	 further	 confirmed	 by	 13C	 NMR	 spectral	 data	
(Table	 3).	 Reaction	 of	 the	 hydrazone	 derivatives	 2	 with	
hydrazine	 hydrate	 afforded	 the	 corresponding	 1‐amino‐2‐
pyridones	 3	 which	 in	 their	 turn,	 were	 allowed	 to	 react	 with	
nitrous	acid	to	give	the	pyridine	derivatives	4.	The	IR	spectra	of	
compounds	 3	 and	 4	 exhibited	 an	 absorption	 band	 at	 1655‐
1668	cm‐1	due	to	the	carbonyl	group	and	a	broad	band	at	3300‐
3370	cm‐1	for	the	NH2	or	NH	absorptions.	Their	structures	were	
further	 supported	 by	 1H	 and	 13C	 NMR	 data	 (Tables	 2	 and	 3).	
Condensation	of	2‐pyridones	3	with	the	appropriate	isocyanate	
and	 isothiocyanate	derivatives	 in	pyridine	as	alkaline	medium	
afforded	 the	 corresponding	 ureas	 5	 and	 thioureas	 6,	
respectively.	 The	 IR	 spectra	 of	 these	 compounds	 exhibited	 a	
urea	carbonyl	band	at	1647‐1668	cm‐1	in	case	of	compounds	5	





respectively	 (Table	 2).	 Their	 13C	 NMR	 spectra	 (Tables	 3)	
showed	 characteristic	 signals	 at	 	 163.2	 and	 181.5‐185.6	
corresponding	to	the	CO	and	CS,	respectively.	
On	the	other	hand,	condensing	the	2‐pyridones	3	with	the	
appropriate	 aldehyde	 gave	 rise	 to	 the	 corresponding	 1‐
arylideneamino	 derivatives	 7.	 Their	 1H	 NMR	 spectra	 are	
characterized	by	the	presence	of	singlets	at		8.12	to	8.24	due	
to	 the	 CH=N	proton	 (Table	 2).	Moreover,	 reacting	 1‐amino‐2‐
pyridones	 3	 with	 benzenesulfonyl	 chloride	 and	 p‐toluene‐
sulfonyl	 chloride	 in	 the	 presence	 of	 pyridine	 led	 to	 the	
formation	 of	 the	 N‐substituted	 benzenesulfonyl	 derivative	 8.	
Their	 IR	 spectra	 showed	 two	 absorption	 bands	 at	 1173‐1185	
cm‐1	and	1338‐1345	cm‐1	for	the	SO2N	groups.	Their	structures	
were	further	supported	by	1H	and	13C	NMR	data	(Tables	2	and	
3).	 Furthermore	 condensation	 of	 the	 2‐pyrone	 hydrazone	 2b	
with	 different	 isocyanates	 and	 isothiocyanates	 yield	 the	
corresponding	 substituted	 sulfonylureido	 and	 sulfonyl‐
thioureido	derivatives	9	 and	10,	 respectively	 (Scheme	2).	The	
IR	spectra	of	derivatives	9	showed	the	sulfonylureido	carbonyl	
absorption	at	1658‐1662	cm‐1,	whereas	those	of	derivatives	10	
were	 characterized	 by	 the	 presence	 of	 the	 C=S	 absorption	 at	
1120‐1150	 cm‐1.	 The	 1H	 NMR	 spectra	 of	 urea	 and	 thiourea	
derivatives	 9	 and	 10,	 revealed	 the	 new	 NH	 protons	 at	 their	





ureido	 and	 thioureido	 nitrogens	 and	 the	 respective	
substituents	 (Table	2).	Their	 13C	NMR	spectra	are	recorded	 in	
Table	4	which	showed	a	urea	carbonyl	carbon	at	163.8	and	a	
thiocarbonyl	 carbon	 at	 186.4	 for	 compounds	 9a	 and	 10a,	
respectively.	 Finally,	 reacting	 the	2‐pyridone	3b	with	2	moles	
of	 the	 appropriate	 isocyanate	 or	 isothiocyanate	 in	 pyridine,	
afforded	 the	 corresponding	 substituted	 sulfonylureido	 and	
thioureido	 analogs	 11	 and	 12,	 respectively.	 Their	 IR	 and	 1H	






Compounds,	 2a‐c,	 3a‐c,	 4a,	 5a‐d,	 6a,b,	 7a‐c,	 8a,b,	 9a‐c,	
10a,b,	 11a‐c,	 12a,	 were	 evaluated	 for	 their	 in	 vitro	
antimicrobial	 activity	 against	 Staphylococcus	 aureus	 (ATCC	
25923)	and	Bacillus	subtilis	(ATCC	6051)	as	examples	of	Gram	
positive	 bacteria,	 Escherichia	 coli	 (ATCC	 25922)	 and	
Pseudomonas	 aeruginosa	 (ATCC	 27853)	 as	 examples	 of	 Gram	
negative	 bacteria,	 Candida	 albicans	 (ATCC	 10231)	 and	
Aspergillus	niger	(recultured)	as	representatives	of	 fungi.	Agar	
diffusion	 method	 was	 used	 for	 the	 determination	 of	 the	
preliminary	 antibacterial	 and	 antifungal	 activity.	 Ampicillin	
trihydrate	 and	 clotrimazole	were	used	 as	 reference	drug.	 The	
results	were	recorded	for	each	tested	compound	as	the	average	
diameter	of	inhibition	zones	(IZ)	of	bacterial	growth	around	the	
discs	 in	 mm.	 The	 minimum	 inhibitory	 concentration	 (MIC)	
measurement	 was	 determined	 for	 compounds	 that	 showed	
significant	 growth	 inhibition	 zones	 (≥	12	mm)	using	 the	 two‐
fold	serial	dilution	method	[39].	The	IZ	(mm)	and	MIC	(µg/mL)	
values	are	recorded	in	Table	4.	
The	 results	 revealed	 that	 most	 of	 the	 tested	 compounds	
displayed	greater	 inhibitory	effect	on	the	growth	of	 the	tested	
Gram	positive	strain	compared	to	Gram	negative	ones.	Most	of	
the	 compounds	 showed	 weak	 or	 no	 antibacterial	 activity	
against	 the	 Gram	 negative,	 P.	 aeruginosa.	 Moreover,	 few	
compounds	 were	 able	 to	 exert	 potential	 antifungal	 activity	





2‐one	 isosteres,	 as	 evidenced	 by	 their	 IZ	 diameters	 and	 MIC	
values	recorded	in	Table	4.	
Among	the	pyran‐2‐one	series,	compound	2a	showed	weak	
antimicrobial	 activity	 against	 all	 the	 tested	 microbial	 strains	
(IZ≤	12	mm).	Introduction	of	chlorine	atom	in	the	phenyl	group	
of	 the	 hydrazone	 moiety	 as	 in	 2c	 resulted	 in	 a	 slight	
improvement	in	the	activity	against	the	Gram	positive	S.	aureus	
and	B.	 subtilis	 (MIC	 values	100	and	200	µg/mL,	 respectively).	
Whereas,	replacement	of	the	chlorine	atom	in	2c	with	sulfamyl	
group	 resulted	 in	 a	 more	 potent	 compound	 2b,	 with	 an	
appreciable	broad	spectrum	of	antibacterial	activity	against	the	
tested	Gram	positive,	Gram	negative	bacteria	(MIC	values	100‐
200	 µg/mL),	 and	 moderate	 antifungal	 activity	 towards	 C.	
albicans	(MIC	100	µg/mL).	On	the	other	hand,	bioisosteric	shift	
from	the	pyran‐2‐one	to	the	pyridine‐2‐one	structure	resulted	
in	 an	 obvious	 improvement	 in	 the	 antimicrobial	 spectrum	 of	
the	target	compounds	(Table	4).	In	this	view,	the	prototype	4a	
displayed	 an	 appreciable	 activity	 against	 the	 Gram	positive	 S.	
aureus	 and	 B.	 subtilis	 (MIC	 50	 and	 100	 µg/mL,	 respectively)	
when	 compared	 with	 the	 bioisosteric	 pyran‐2‐one	 2a.	
Introduction	 of	 an	 amino	 group	 at	 position‐1	 in	 the	 pyridine	
ring	 as	 in	 compound	 3c	 resulted	 in	 significant	 change	 of	 the	
overall	 antimicrobial	 spectrum.	 It	 showed	 two‐fold	
improvement	in	the	potency	against	B.	subtilis	when	compared	
with	4a	(MIC	50	νs	100	µg/mL,	respectively),	while	it	revealed	
moderate	 activity	 against	 E.	 coli	 (MIC	 200	 µg/mL).	 It	 also	
showed	antifungal	activity	towards	C.	albicans	(MIC	50	µg/mL).	
Furthermore,	 replacement	 of	 the	 1‐amino	 group	 in	3a	with	 a	
urea	 moiety	 (compound	 5a	 produced	 the	 most	 potent	
antimicrobial	 activity	 in	 the	 current	 series	 of	 compounds.	
Compound	 5a	 is	 as	 potent	 as	 ampicillin	 (MIC	 12.5	 µg/mL)	
against	S.	aureus,	whereas	 its	activity	against	B.	subtilis	and	E.	
Coli	 was	 50%	 lower	 than	 that	 of	 ampicillin	 (MIC	 50	 νs	 25	
µg/mL,	 respectively).	 Moreover,	 it	 displayed	 a	 remarkable	
antifungal	activity	towards	C.	albicans,	which	was	about	50%	of	
that	 of	 Clotrimazole	 (MIC	 25	 νs	 12.5	 µg/mL,	 respectively).	
However,	it	is	worthy	to	mention	that,	structure	modification	of	









Cantos	 et	 al.	 [40].	 A	 strain	 of	 Mycobacterium	 tuberculosis	
(locally	 isolated,	Alexandria,	 Egypt)	was	utilized	 in	 this	 assay.	
Rifampicin	and	isonicotinic	acid	hydrazide	(INH)	were	used	as	
reference	antimycobacterial	drugs.	The	MIC	was	defined	as	the	
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